Volume 3 Supplement 1

23rd Congress of the International Association for Breast Cancer Research

Open Access

A novel sodium phenylacetate-dextran derivative ester inhibits the growth and angiogenesis of MCF-7ras breast cancer xenografts

  • M Di Benedetto1,
  • D Briane1,
  • O Oudar1,
  • O Sainte Catherine1,
  • J Jozefonvicz2,
  • M Kraemer1 and
  • M Crépin1
Breast Cancer Research20013(Suppl 1):A21


Received: 10 May 2001

Published: 31 May 2001

We previously showed that sodium phenylacetate (NaPa) and carboxymethyl benzylamide dextran (CMDB) are both able to block the tumor growth of the breast cancer cell line MCF-7ras in athymic mice. In this study, we studied the effect of a new molecule: a CMDB esterified by phenylacetic acid (NaPaC). In vitro, NaPaC can inhibit threefold to fourfold more MCF-7ras proliferation than NaPa alone. Furthermore, we showed that the antiproliferative activity of NaPaC was dependent on phenylacetate substitution. In vivo studies showed that a very low dose of NaPaC (15 mg/kg) inhibited the MCF-7ras tumor growth of 60% without animal toxicity. The inhibition of tumor growth was concomitant with a reduction in angiogenesis and an increase in necrosis. Moreover, we demonstrated that NaPaC inhibited the paracrine mitogenic effect of MCF-7ras conditioned medium (CM) on fibroblasts and endothelial cells proliferation.

Authors’ Affiliations

UPRES 2360, Equipe d'Oncologie cellulaire et moléculaire des tumeurs SMBH, Université Paris
Laboratoire de Recherches sur les Macromolécules (LRM), Institut Galilée, Université Paris


© BioMed Central Ltd 2001